Response to the ‘Comment on the editorial by Turner et al. on Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.’

European Heart Journal - Cardiovascular Pharmacotherapy